Impact of bone marrow pathology on the clinical management of Philadelphia chromosome - Negative myeloproliferative neoplasms

Clinical Lymphoma, Myeloma and Leukemia

Volumn 15, Issue 5, 2015, Pages 253-261

  Pozdnyakova, Olga ^a   Hasserjian, Robert P ^b   Verstovsek, Srdan ^c   Orazi, Attilio ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Bone marrow fibrosis; Essential thrombocythemia; Polycythemia vera; Primary myelofibrosis; Ruxolitinib

Indexed keywords

ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; COLLAGEN; JANUS KINASE; JANUS KINASE INHIBITOR; RETICULIN; RUXOLITINIB; STAT PROTEIN; PYRAZOLE DERIVATIVE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW DISEASE; CYTOGENETICS; HUMAN; LEUKEMIA; MALIGNANT TRANSFORMATION; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; OSTEOSCLEROSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHILADELPHIA CHROMOSOME NEGATIVE CELL; POLYCYTHEMIA VERA; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SIGNAL TRANSDUCTION; SPLENOMEGALY; SURVIVAL; SYMPTOMATOLOGY; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; BONE MARROW; MYELOPROLIFERATIVE DISORDERS; PATHOLOGY; PHILADELPHIA 1 CHROMOSOME;

BONE MARROW; HUMANS; MYELOPROLIFERATIVE DISORDERS; PHILADELPHIA CHROMOSOME; PYRAZOLES;

EID: 84928304478     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2014.11.002     Document Type: Review

References (83)

1. A. Tefferi, J. Thiele, and A. Orazi et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel Blood 110 2007 1092 1097
2. J.W. Vardiman, J. Thiele, and D.A. Arber et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes Blood 114 2009 937 951
3. N.C. Cross Genetic and epigenetic complexity in myeloproliferative neoplasms Hematology Am Soc Hematol Educ Program 2011 2011 208 214
4. R. Rampal, F. Al-Shahrour, and O. Abdel-Wahab et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis Blood 123 2014 e123 e133
5. J. Nangalia, C.E. Massie, and E.J. Baxter et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2 N Engl J Med 369 2013 2391 2405
6. T. Klampfl, H. Gisslinger, and A.S. Harutyunyan et al. Somatic mutations of calreticulin in myeloproliferative neoplasms N Engl J Med 369 2013 2379 2390
7. P. Lundberg, A. Karow, and R. Nienhold et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms Blood 123 2014 2220 2228
8. F. Passamonti, E. Rumi, and D. Pietra et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications Leukemia 24 2010 1574 1579
9. E. Rumi, D. Pietra, and V. Ferretti et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes Blood 123 2014 1544 1551
10. E. Rumi, D. Pietra, and P. Guglielmelli et al. Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms Blood 121 2013 4388 4395
11. A. Tefferi, P. Guglielmelli, and T.L. Lasho et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients Leukemia 28 2014 1494 1500
12. H. Andrikovics, T. Krahling, and K. Balassa et al. Distinct clinical characteristics in myeloproliferative neoplasms with calreticulin mutations Haematologica 99 2014 1184 1190
13. A. Tefferi, T.L. Lasho, and C.M. Finke et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons Leukemia 28 2014 1472 1477
14. A.M. Vannucchi, T.L. Lasho, and P. Guglielmelli et al. Mutations and prognosis in primary myelofibrosis Leukemia 27 2013 1861 1869
15. A. Tefferi, T. Jimma, and N.H. Sulai et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F Leukemia 26 2012 475 480
16. L. Boiocchi, S. Mathew, and U. Gianelli et al. Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage Mod Pathol 26 2013 1577 1585
17. E. Rumi, A. Harutyunyan, and C. Elena et al. Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm Am J Hematol 86 2011 974 979
18. K. Hussein, A.D. Pardanani, and D.L. Van Dyke et al. International Prognostic Scoring System - independent cytogenetic risk categorization in primary myelofibrosis Blood 115 2010 496 499
19. N. Gangat, D. Caramazza, and R. Vaidya et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status J Clin Oncol 29 2011 392 397
20. F. Cervantes, B. Dupriez, and A. Pereira et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment Blood 113 2009 2895 2901
21. F. Passamonti, F. Cervantes, and A.M. Vannucchi et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) Blood 115 2010 1703 1708
22. A. Tefferi, A. Pardanani, and N. Gangat et al. Leukemia risk models in primary myelofibrosis: an International Working Group study Leukemia 26 2012 1439 1441
23. A. Tefferi, E. Rumi, and G. Finazzi et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study Leukemia 27 2013 1874 1881
24. F. Passamonti, J. Thiele, and F. Girodon et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment Blood 120 2012 1197 1201
25. T. Barbui, J. Thiele, and F. Passamonti et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study J Clin Oncol 29 2011 3179 3184
26. A. Tefferi How I treat myelofibrosis Blood 117 2011 3494 3504
27. G. Barosi, R.A. Mesa, and J. Thiele et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment Leukemia 22 2008 437 438
28. H.M. Kvasnicka WHO classification of myeloproliferative neoplasms (MPN): a critical update Curr Hematol Malig Rep 8 2013 333 341
29. J. Thiele, H.M. Kvasnicka, and L. Mullauer et al. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification Blood 117 2011 5710 5718
30. A. Tefferi, and T. Barbui Personalized management of essential thrombocythemia - application of recent evidence to clinical practice Leukemia 27 2013 1617 1620
31. T. Barbui, J. Thiele, and A. Carobbio et al. Masked polycythemia vera diagnosed according to WHO and BCSH classification Am J Hematol 89 2014 199 202
32. R.T. Silver, W. Chow, and A. Orazi et al. Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis Blood 122 2013 1881 1886
33. T. Barbui, J. Thiele, and A. Carobbio et al. Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients Am J Hematol 89 2014 588 590
34. T. Barbui, J. Thiele, and H. Gisslinger et al. Masked polycythemia vera (mPV): results of an international study Am J Hematol 89 2014 52 54
35. G. Hauck, D. Jonigk, and G. Göhring et al. Myelofibrosis in Philadelphia chromosome-negative myeloproliferative neoplasms is associated with aberrant karyotypes Cancer Genet 206 2013 116 123
36. H.C. Hasselbalch The role of cytokines in the initiation and progression of myelofibrosis Cytokine Growth Factor Rev 24 2013 133 145
37. M.C. Le Bousse-Kerdilès Primary myelofibrosis and the "bad seeds in bad soil" concept Fibrogenesis Tissue Repair 5 suppl 1 2012 S20
38. M.C. Le Bousse-Kerdilès, M.C. Martyré, and M. Samson Cellular and molecular mechanisms underlying bone marrow and liver fibrosis: a review Eur Cytokine Netw 19 2008 69 80
39. H. Kreipe, G. Büsche, O. Bock, and K. Hussein Myelofibrosis: molecular and cell biological aspects Fibrogenesis Tissue Repair 5 suppl 1 2012 S21
40. J.J. Lataillade, O. Pierre-Louis, and H.C. Hasselbalch on behalf of the French INSERM and the European EUMNET networks on myelofibrosis Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence Blood 112 2008 3026 3035
41. G. Barosi, and R.P. Gale Bone marrow fibrosis in myeloproliferative neoplasms-associated myelofibrosis: deconstructing a myth? Leuk Res 35 2011 563 565
42. S. Sozer, and R. Hoffman Laser-capture microdissection and analysis of liver endothelial cells from patients with Budd-Chiari syndrome Methods Mol Biol 755 2011 405 415
43. N. Papadantonakis, S. Matsuura, and K. Ravid Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection Blood 120 2012 1774 1781
44. J. Thiele, H.M. Kvasnicka, A. Schmitt-Graeff, and V. Diehl Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients Leuk Lymphoma 44 2003 949 953
45. J. Thiele, H.M. Kvasnicka, and F. Facchetti et al. European consensus on grading bone marrow fibrosis and assessment of cellularity Haematologica 90 2005 1128 1132
46. O. Pozdnyakova, K. Wu, and A. Patki et al. High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms Mod Pathol 27 2014 1447 1454
47. Kvasnicka HM, Thiele J, Orazi A, et al. Criteria for therapy response and progression in patients with myelofibrosis based on bone marrow features [abstract 1410]. Paper presented at: 103rd USCAP Annual Meeting; March 1-7, 2014; San Diego, Calif.
48. U. Gianelli, C. Vener, and A. Bossi et al. The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis Mod Pathol 25 2012 1193 1202
49. D. Lekovic, M. Gotic, and M. Perunicic-Jovanovic et al. Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis Med Oncol 31 2014 869
50. A. Nazha, Z. Estrov, and J. Cortes et al. Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis Leuk Lymphoma 54 2013 2537 2539
51. P.J. Campbell, D. Bareford, and W.N. Erber et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy J Clin Oncol 27 2009 2991 2999
52. T. Barbui, J. Thiele, and F. Passamonti et al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome Blood 119 2012 2239 2241
53. N. Kröger, M. Kvasnicka, and J. Thiele Replacement of hematopoietic system by allogeneic stem cell transplantation in myelofibrosis patients induces rapid regression of bone marrow fibrosis Fibrogenesis Tissue Repair 5 suppl 1 2012 S25
54. N. Kröger, J. Thiele, and A. Zander et al. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis Exp Hematol 35 2007 1719 1722
55. N. Kröger, T. Zabelina, and H. Alchalby et al. Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis Biol Blood Marrow Transplant 20 2014 812 815
56. M. Hultdin, G. Sundström, and A. Wahlin et al. Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment Med Oncol 24 2007 63 70
57. T. Stauffer Larsen, M.B. Møller, and K. de Stricker et al. Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission Hematology 14 2009 331 334
58. M.A. Domingues, A.T. Haepers, and I.H. Massaut et al. Reversal of bone marrow fibrosis in idiopathic myelofibrosis after treatment with alpha-interferon Haematologica 83 1998 1124 1125
59. R.T. Silver, and K. Vandris Recombinant interferon alpha (rIFNα-2b) may retard progression of early primary myelofibrosis Leukemia 23 2009 1366 1369
60. R.T. Silver, K. Vandris, and J.J. Goldman Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report Blood 117 2011 6669 6672
61. Zhou J, Gong P, Silver RT, et al. Recombinant interferon alpha therapy decreases bone marrow fibrosis and cellularity and improves megakaryocyte morphology in a significant portion of patients with myelofibrosis [abstract 1597]. Paper presented at: 103rd USCAP Annual Meeting; March 1-7, 2014; San Diego, Calif.
62. A. Berrebi, E. Feldberg, I. Spivak, and L. Shvidel Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly Haematologica 92 2007 e15 e16
63. A. Quintás-Cardama, H.M. Kantarjian, and T. Manshouri et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis J Clin Oncol 27 2009 4760 4766
64. S. Verstovsek, R.A. Mesa, and J. Gotlib et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis N Engl J Med 366 2012 799 807
65. C. Harrison, J.J. Kiladjian, and H.K. Al-Ali et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis N Engl J Med 366 2012 787 798
66. S. Verstovsek, R.A. Mesa, and J. Gotlib et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis Br J Haematol 161 2013 508 516
67. S. Verstovsek, R.A. Mesa, and J. Gotlib et al. Long-term outcomes of ruxolitinib therapy in patients with myelofibrosis: 3-year update from COMFORT-I [abstract] Blood 122 2013 396
68. S. Verstovsek, R.A. Mesa, and J. Gotlib et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I Haematologica 98 2013 1865 1871
69. F. Cervantes, A.M. Vannucchi, and J.J. Kiladjian et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis Blood 122 2013 4047 4053
70. F. Passamonti, M. Maffioli, and F. Cervantes et al. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts Blood 123 2014 1833 1855
71. B.S. Wilkins, D. Radia, and C. Woodley et al. Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib Haematologica 98 2013 1872 1876
72. M. Molica, A. Serrao, and R. Saracino et al. Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve? Ann Hematol 93 2014 1951 1952
73. S. Verstovsek, H. Kantarjian, and R.A. Mesa et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis N Engl J Med 363 2010 1117 1127
74. H.M. Kvasnicka, J. Thiele, and C.E. Bueso-Ramos et al. Exploratory analysis of the effect of ruxolitinib on bone marrow morphology in patients with myelofibrosis [abstract 7030] J Clin Oncol 31 suppl 2013
75. H.M. Kvasnicka, J. Thiele, and C.E. Bueso-Ramos et al. Effects of five-years of ruxolitinib therapy on bone marrow morphology in patients with myelofibrosis and comparison with best available therapy [abstract] Blood 122 2013 4055
76. H.M. Kvasnicka, J. Thiele, and C.E. Bueso-Ramos et al. Effects of ruxolitinib therapy on megakaryocyte morphology and inflammatory bone marrow reaction in patients with myelofibrosis [abstract] Blood 122 2013 4056
77. C.H.M. Jamieson, R.P. Hasserjian, and J. Gotlib et al. Effect of treatment with the JAK2-selective inhibitor fedratinib (SAR302503) on bone marrow histology in patients with myeloproliferative neoplasms with myelofibrosis [abstract] Blood 122 2013 2823
78. S. Verstovsek, R.A. Mesa, and S.K. Rhoades et al. Phase I study of the JAK2 V617F inhibitor, LY2784544, in patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) [abstract] Blood 118 2011 2814
79. J. Mascarenhas, M. Lu, and T. Li et al. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF) Br J Haematol 161 2013 68 75
80. A. Tefferi, K. Begna, and R.R. Laborde et al. Imetelstat, a telomerase inhibitor, induces morphologic and molecular remissions in myelofibrosis and reversal of bone marrow fibrosis [abstract] Blood 122 2013 662
81. A. Kirabo, S.O. Park, and H.L. Wamsley et al. The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis Am J Pathol 181 2012 858 865
82. S. Verstovsek, R.A. Mesa, and L.M. Foltz et al. Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrois: stage 1 results [abstract 7114] J Clin Oncol 32 suppl 2014
83. A. Manoharan, R. Horsley, and W.R. Pitney The reticulin content of bone marrow in acute leukaemia in adults Br J Haematol 43 1979 185 190